维生素D_3与非酒精性脂肪性肝炎的研究进展  

Research progress on vitamin D_3 and non-alcoholic steatohepatitis

作　　者：韩红梅[1] 朴熙绪[1] 

机构地区：[1]延边大学附属医院消化内科,吉林延吉133000

出　　处：《基础医学与临床》2015年第12期1705-1708,共4页Basic and Clinical Medicine

摘　　要：非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病(NAFLD)的最重要形式,可发展为肝硬化和肝癌。在啮齿类动物中发现维生素D3(VD3)具有抗氧化、抗凋亡、抗感染和抗肝纤维化的作用。补充VD3可部分改善NASH的进展。VD3有望成为临床治疗NASH的有效药物。Non-alcoholic steatohepatitis （NASH） is recognized as the most severe form of non-alcoholic fatty liver disease （NAFLD）, with likely progression to liver cirrhosis and hepatoeellular carcinoma. Vitamin D3 （VD3 ） has been shown to act as an anti-oxidant, anti-apoptotic, anti-inflammatory and anti-fibrotic compound in rodents. VD3 supplementation partly ameliorated the NASH progression and thus can be an effective approach for the intervention in clinical NASH.

关 键 词：维生素D3 非酒精性脂肪性肝炎 

分 类 号：R575[医药卫生—消化系统]